<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01905475</url>
  </required_header>
  <id_info>
    <org_study_id>POL6326-POL-006</org_study_id>
    <nct_id>NCT01905475</nct_id>
  </id_info>
  <brief_title>CXCR4 Antagonism for Cell Mobilisation and Healing in Acute Myocardial Infarction (CATCH-AMI)</brief_title>
  <acronym>CATCH-AMI</acronym>
  <official_title>CXCR4 AnTagonism for Cell Mobilisation and Healing in Acute Myocardial Infarction (CATCH-AMI). A Phase IIa, Double-Blind, Placebo-Controlled, Randomised, Multi-centre Study of POL6326, a CXCR4 Antagonist, in Patients With Large Reperfused ST Elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Polyphor Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Polyphor Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effects of POL6326 (CXCR4 antagonist) as a
      stem cell mobilizing agent, on cardiac function and infarct size and on safety and
      tolerability, in patients with reperfused ST-Elevation Myocardial Infarction (STEMI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After acute myocardial infarction and successful stent implantation patients will undergo a
      baseline MRI (magnetic resonance imaging) for eligibility for the study. Patients will
      receive POL6326 or placebo in the first week after STEMI. The primary and secondary endpoints
      will also be determined in a follow-up visit after 12 months. An interim analysis will be
      performed after 50% of the patients have completed the 4 months MRI assessment and may result
      in an adjustment of study size. A number of pre-specified subgroups will be investigated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in LVEF (left ventricular ejection fraction) as determined by MRI</measure>
    <time_frame>4 months</time_frame>
    <description>Difference in LVEF from baseline (after STEMI and stent procedure, before infusion of drug or placebo) and after 4 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Additional measures of cardiovascular function</measure>
    <time_frame>4 months</time_frame>
    <description>Using MRI the following parameters will also be determined: infarct size, LV volumes, regional LV function. Plasma BNP (brain natriuretic peptide) will also be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mobilization of stem and progenitor cells</measure>
    <time_frame>2 days</time_frame>
    <description>Time dependent measurement of stem and progenitor cells during and after infusion of POL6326</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic outcome</measure>
    <time_frame>2 days</time_frame>
    <description>Measurement of plasma concentrations of POL6326 at predose and several time points after infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of POL6326 by intravenous infusion</measure>
    <time_frame>12 months</time_frame>
    <description>Safety as measured by incidence, type and severity of adverse events (Major Adverse Cardiovascular Events (MACE), Arrhythmia)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Large Reperfused ST-Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>POL6326</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>POL6326 intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>POL6326</intervention_name>
    <arm_group_label>POL6326</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with symptoms suggestive of an acute MI with ST-segment elevation or new left
             bundle-branch block and a rise or fall in cardiac necrosis markers.

          2. Patients must be scheduled to undergo coronary angiography for the purposes of primary
             PCI (percutaneous coronary intervention) culminating in successful stent implantation.

          3. Age between 18 and 80 years. Male and WOCBP (women of child bearing potential) willing
             to use highly effective methods of contraception from the time of first dose until 3
             months after the last dose of the drug.

          4. Markedly reduced LVEF at baseline cardiac MRI.

          5. No previous occurrence of Myocardial Infarction.

          6. Estimated glomerular filtration rate (eGFR) equal or higher than 40 mL/minute prior to
             MRI.

          7. Signed Informed Consent.

        Exclusion Criteria:

          1. Evidence of multi-vessel coronary artery disease likely to require repeat PCI or
             coronary artery bypass grafting within 4 months.

          2. Pulmonary oedema or cardiogenic shock requiring intubation or mechanical support at
             the time of the planned baseline MRI.

          3. Fitted with a non-MRI-compatible cardiac pacemaker or implantable cardioverter
             defibrillator, or expected to require such a device within 4 months after
             randomisation.

          4. Terminal illness or malignant disease.

          5. Advanced hepatic disease.

          6. Diagnosis of severe obesity which precludes MRI assessments.

          7. Claustrophobia.

          8. Acute systemic infection or fever.

          9. Anemia (where hemoglobin levels are &lt;10 g/dL), thrombocytopenia (platelet count
             &lt;100000/μL) or coagulopathy.

         10. History of multiple drug allergies or with a known allergy to the drug class of CXCR4
             antagonists.

         11. Pregnancy or females of childbearing potential who are not using double contraception

         12. Known history of human immunodeficiency virus (HIV) infection, chronic hepatitis B or
             hepatitis C infection or significant active chronic inflammatory disease that requires
             immunosuppressive medication or regular systemic corticosteroids.

         13. Patients who have participated in any investigational drug or device trial within 30
             days prior to signing informed consent.

         14. Patients who are unwilling or unable to abide by the study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kai C. Wollert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff-Klinik GmbH</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Campus Benjamin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Campus Virchow</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magyar Honvédség Egészségügyi Központ, Kardiológiai osztály</name>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DEOEC, Kardiológiai Intézet</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaposi Mór Teaching Hospital</name>
      <address>
        <city>Kaposvár</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pécs University</name>
      <address>
        <city>Pecs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zala Megyei Kórház,Kardiológia</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital John Paul II</name>
      <address>
        <city>Krakow</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edinburgh Heart Centre Royal Infirmary</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West of Scotland Regional Heart &amp; Lung Center, Golden Jubilee National Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G81 4DY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Leicester NHS Trust Glenfield Hospital</name>
      <address>
        <city>Leicester</city>
        <zip>LE3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Norway</country>
  </removed_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2013</study_first_submitted>
  <study_first_submitted_qc>July 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2013</study_first_posted>
  <last_update_submitted>June 9, 2016</last_update_submitted>
  <last_update_submitted_qc>June 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>STEMI</keyword>
  <keyword>AMI</keyword>
  <keyword>repair</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

